OABI
OmniAb, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.31
−9.26%Aug 17, 2026, 10:01 UTC
OmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.
Aug 6, 2026, 20:05 UTC
OmniAb, Inc. reported financial results for the three and six months ended June 30, 2026, and updated its 2026 financial guidance, increasing revenue and cash outlook based on continued business momentum.
Jul 27, 2026, 11:00 UTC
VERAXA Biotech advanced its bispecific antibody drug conjugate program VXA-222 into the next phase after achieving a key technical milestone from a joint discovery collaboration with OmniAb.
Jul 13, 2026, 12:00 UTC
OmniAb appointed Amechi Nwachuku as Executive Vice President and Chief Operating Officer, effective July 13, 2026.
Source: